evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%

Cannabinoids vs placebo

Behavioural and psychological symptoms of dementia (BPSD) · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review

Cannabinoids vs placebo

Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review

Cannabinoids vs placebo

Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

Comparison: cannabinoids showed no clear difference in adverse events ‐ nervous system disorders ‐ total nervous system… compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids vs placebo

Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids vs placebo

Adverse event: gastrointestinal disorders at 1‐month (with actual · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

Comparison: cannabinoids showed no clear difference in adverse events ‐ gastrointestinal disorders ‐ total gastrointestinal… compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids vs placebo

Adverse effects: 1. General ‐ overall number of events · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

Comparison: cannabinoids showed no clear difference in adverse events ‐ general ‐ total general adverse events ( compared with placebo (low certainty).

1 finding from 1 review